



7th August 2013

National Stock Exchange
Exchange Plaza, 5th Floor,
Plot No. C/1 G Block
Bandra – Kurla Complex
Bandra (East), Mumbai 400 051

GlaxoSmithKline
Pharmaceuticals Limited
Regd. Office: GSK House,
Dr. Annie Besant Road,
Worli, Mumbai - 400030.

Tel: +91 22 2495 9595
Fax: +91 22 2495 9494

Dear Sir,

Sub: Intimation under Clause 36 of the Listing Agreement

This is to inform you that the Government of India revised the Drug Policy and enunciated the National Pharmaceutical Pricing Policy 2012 (NPPP 2012), the Government has adopted the list of medicines that had been revised by the Ministry of Health and Family Welfare and which formed part of the National List of Essential Medicines (NLEM). As per the above under the NPPP 2012, the span of price control of drugs has been enhanced from 74 to 348 drugs and the pricing mechanism has been amended from cost based pricing to market based pricing. The government in order to implement the above, promulgated the new Drug Price Control Order 2013 (DPCO 2013) and the same has come into effect in May 2013. In line with the said DPCO 2013, the Government of India has periodically notified the new price of essential drugs.

In view of the above, a number of products of the Company have come under the DPCO 2013 resulting in reduction of prices of companies drugs. The new reduced notified price is to be implemented within a period of 45 days from the date of Notification of the price control order. The Company estimates 5% impact on an annualized basis on its sales and turnover.

This should be treated as intimation under Clause 36 of the Listing Agreement.

Yours faithfully
GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni
General Manager – Administration
& Company Secretary